Kyntra Bio (NASDAQ:KYNB – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Kyntra Bio to related businesses based on the strength of its institutional ownership, earnings, profitability, valuation, dividends, analyst recommendations and risk.
Insider and Institutional Ownership
72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Kyntra Bio and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kyntra Bio | 2,199.13% | N/A | -47.27% |
| Kyntra Bio Competitors | -12,224.09% | -202.33% | -31.23% |
Analyst Ratings
This is a summary of current ratings for Kyntra Bio and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kyntra Bio | 1 | 1 | 5 | 0 | 2.57 |
| Kyntra Bio Competitors | 9923 | 15317 | 45694 | 1603 | 2.54 |
Kyntra Bio currently has a consensus target price of $36.80, suggesting a potential upside of 1,055.42%. As a group, “Biotechnology” companies have a potential upside of 131.06%. Given Kyntra Bio’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Kyntra Bio is more favorable than its rivals.
Volatility and Risk
Kyntra Bio has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Kyntra Bio’s rivals have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.
Valuation and Earnings
This table compares Kyntra Bio and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Kyntra Bio | $4.62 million | $183.45 million | 0.07 |
| Kyntra Bio Competitors | $768.41 million | $11.71 million | -18.32 |
Kyntra Bio’s rivals have higher revenue, but lower earnings than Kyntra Bio. Kyntra Bio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Kyntra Bio beats its rivals on 9 of the 13 factors compared.
Kyntra Bio Company Profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
